Management of Gastrocardiac Syndrome

Initial Cardiac Evaluation

In patients with suspected gastrocardiac syndrome, immediately rule out acute coronary syndrome with ECG and cardiac biomarkers before attributing symptoms to GI causes, as the mortality risk of missing cardiac disease far outweighs the risk of over-investigation 1, 2
Obtain 12-lead ECG within 10 minutes of presentation for any chest pain or palpitations, regardless of suspected GI etiology 1
Measure high-sensitivity cardiac troponin immediately upon presentation, with serial measurements to identify rising/falling patterns 1
Perform serial ECGs every 15-30 minutes during the first hour if symptoms persist or recur, even if initial ECG is normal or shows only non-specific changes 1
Consider posterior leads (V7-V9) if standard 12-lead is non-diagnostic but clinical suspicion remains intermediate-to-high, as posterior wall ischemia can be electrically silent 1
A single normal ECG never rules out ACS—up to 6% of patients with evolving ACS are inappropriately discharged with normal initial ECGs 1
Non-specific ST-T wave changes do not exclude acute coronary syndrome 3

Administer aspirin 162-325 mg (non-enteric, chewed) immediately unless documented aspirin allergy or active/recent GI bleeding 4, 5, 3
The presence of GI history does not contraindicate aspirin if there is no active bleeding 4, 5
Withhold aspirin only if: documented allergy, active peptic ulcer with bleeding, hematemesis, melena, or recent significant GI hemorrhage 6, 5

Repeat cardiac evaluation if symptoms change or fail to improve with GI-directed therapy 1
Avoid attributing new or worsening symptoms to GI causes without repeat cardiac workup—always maintain high index of suspicion for true cardiac disease 1, 2
Never diagnose gastrocardiac syndrome as a primary diagnosis without first completing comprehensive cardiac evaluation including serial ECGs, troponins, and risk stratification 1, 2
The American College of Cardiology recommends that patients with suspected gastrocardiac syndrome undergo comprehensive cardiac evaluation before initiating GI-directed therapy, due to the high risk of missed ACS 1, 2

The American Gastroenterological Association explicitly states that cardiac etiology must be "carefully considered" before accepting a diagnosis of reflux chest pain syndrome, specifically because the morbidity and mortality of ischemic heart disease substantially exceeds that of GERD 8, 9
The American College of Cardiology recommends that patients with chest pain and dyspnea undergo physical examination specifically assessing for signs of heart failure, including fine rales over lung fields, distended neck veins, peripheral edema, and third heart sound (S3 gallop) 10
Plasma natriuretic peptide levels (BNP or NT-proBNP) are recommended in all patients with acute dyspnea to differentiate acute heart failure from non-cardiac causes, with a strength of evidence supported by the European Heart Journal and European Journal of Heart Failure 11, 12

When chest pain presents with dyspnea, the diagnostic sequence must be: acute coronary syndrome (ECG + troponin), acute heart failure (BNP + echocardiography), pulmonary embolism (if indicated by risk factors), and only then consider GI causes 10, 13
The ESC Guidelines describe a "vicious circle" that leads to progressive myocardial dysfunction, worsening cardiac output, end-organ damage, and death if acute heart failure goes untreated 10, 12

This case represents a clear deviation from standard of care, with multiple guidelines from the ESC, ACC/AHA, and AGA emphasizing that cardiac causes must be excluded before attributing chest pain and dyspnea to non-cardiac etiologies 8, 9, 10, 11, 12, 13